Syndax News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Syndax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Syndax Today - Breaking & Trending Today
Treatment with the first-in-class menin inhibitor revumenib generated complete remissions or complete remissions with partial hematological recovery in adult and pediatric patients with relapsed/refractory acute myeloid leukemia or acute lymphoblastic leukemia harboring KMT2A rearrangements. ....
The anti–CSF-R1 antibody axatilimab generated responses in adult and pediatric patients with chronic graft-vs-host disease who received 2 or more prior lines of therapy, meeting the primary end point in all cohorts of patients in the phase 2 AGAVE-201 trial. ....
Item 1.02 Termination of a Material Definitive Agreement.
As previously disclosed, on March 22, 2021, Syndax Pharmaceuticals, Inc. entered into a sales agreement with Cowen and Company, LLC ,. | May 26, 2023 ....
WALTHAM, Mass. — WALTHAM, Mass. — Syndax Pharmaceuticals Inc. on Monday reported a loss of $41.1 million in its first quarter. The Waltham, Massachusetts-based company said it had. | May 8, 2023 ....